Boston Scientific (NYSE:BSX) Price Target Cut to $96.00 by Analysts at Evercore ISI

Boston Scientific (NYSE:BSX) had its target price reduced by Evercore ISI from $112.00 to $96.00 in a research note released on Thursday, MarketBeat Ratings reports. They currently have an outperform rating on the medical equipment provider’s stock.

BSX has been the subject of a number of other research reports. Morgan Stanley lowered their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday. Stifel Nicolaus lowered their price objective on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a research report on Wednesday. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, January 21st. Needham & Company LLC decreased their target price on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Robert W. Baird dropped their price target on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $109.32.

Boston Scientific Price Performance

Boston Scientific stock opened at $77.60 on Thursday. The firm has a fifty day moving average of $93.90 and a 200-day moving average of $98.98. Boston Scientific has a 52-week low of $74.86 and a 52-week high of $109.50. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $115.04 billion, a P/E ratio of 40.00, a PEG ratio of 1.33 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the prior year, the company earned $0.70 EPS. The firm’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, analysts predict that Boston Scientific will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

Several institutional investors and hedge funds have recently bought and sold shares of the company. Requisite Capital Management LLC bought a new position in Boston Scientific during the 4th quarter worth approximately $458,000. RiverFront Investment Group LLC increased its holdings in shares of Boston Scientific by 0.7% in the 4th quarter. RiverFront Investment Group LLC now owns 21,308 shares of the medical equipment provider’s stock valued at $2,032,000 after acquiring an additional 150 shares during the last quarter. Passumpsic Savings Bank acquired a new stake in shares of Boston Scientific during the 4th quarter valued at approximately $3,141,000. North Dakota State Investment Board bought a new position in Boston Scientific during the fourth quarter worth $4,826,000. Finally, Elyxium Wealth LLC boosted its holdings in Boston Scientific by 4.4% in the fourth quarter. Elyxium Wealth LLC now owns 5,283 shares of the medical equipment provider’s stock worth $504,000 after purchasing an additional 221 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 results beat Wall Street: Boston Scientific reported $0.80 EPS and $5.29B in sales (sales +15.9%), showing solid underlying growth that supports the company’s long-term story. PR: Q4 results
• Positive Sentiment: Analysts still mostly constructive: Many firms kept buy/overweight ratings and continue to model meaningful upside even after trimming forecasts — that backing can attract buyers after the drop. Benzinga: analysts cutting forecasts
• Neutral Sentiment: Planned board departure announced — a governance change (long‑serving director stepping down) that is notable but not an operational shock. TipRanks: board departure
• Neutral Sentiment: Unusual options activity and heavy put buying increased volatility — option flows amplified the move and can accelerate selloffs or rebounds depending on market makers’ hedging. Barchart: options activity
• Negative Sentiment: Soft 2026 guidance and underperformance in electrophysiology: management gave a cautious revenue/quarterly outlook and flagged weaker EP sales, which triggered the earlier large selloff as it reset near-term growth expectations. Reuters: cautious outlook
• Negative Sentiment: Multiple price-target cuts: several banks trimmed targets (some steeply) after the print — that lowers analyst floor and can weigh on recovery momentum. Benzinga: PT cuts
• Negative Sentiment: New investor class-action inquiry: Levi & Korsinsky announced an investigation into BSX related to the Feb. 4 results, which is a legal overhang until resolved. Newsfile: securities probe
• Negative Sentiment: CEO insider sale disclosed (large block sold in early Feb.) — raises near‑term sentiment concerns even if not unusual for executives. SEC filing: insider sale

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.